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Objectives: The aim of our study was to determine if redox imbalance caused by the activities of antioxidant
enzymes existed in erythrocytes of type 1 myotonic dystrophy (DM1) patients.
Methods: The activities of erythrocyte superoxide dismutase, catalase, glutathione peroxidase, and
glutathione reductase were measured in 30 DM1 patients and 15 healthy controls (HCs). The obtained
values were correlated with the Muscular Impairment Rating Scale (MIRS) score and creatine kinase (CK).
Results: Superoxide dismutase and catalase activities were lower in DM1 patients compared to HCs. A
positive correlation was found between disease duration and MIRS score as well as with glutathione
reductase activity. In DM1 patients, there were positive correlations between catalase, glutathione
peroxidase, and glutathione reductase activities. After sub-dividing DM1 patients according to CK levels,
superoxide dismutase activity was still statistically different from HCs. However, catalase activity was
significantly lower only in DM1 patients with increased CK.
Discussion: Undesirable alterations in antioxidant enzyme activities during DM1 disease progression may
result in conditions favoring oxidative stress and changes in metabolism which together could contribute
to muscle wasting.
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Introduction
Type 1 myotonic dystrophy (DM1) is the most common
form of muscular dystrophy in adults with a worldwide
prevalence of 1–35 patients per 100 000 inhabitants.1
DM1 is an autosomal-dominant disease caused by
the expansion of Cytosin, Thymine, Guanine (CTG)
trinucleotide repeats within the non-coding 3′-untrans-
lated region of the gene encoding dystrophia myoto-
nica-protein kinase on chromosome locus 19q13.3.2
This mutation has a trans-dominant effect through
the regulation of alternative splicing of pre-messenger
RNA for various proteins, mRNA translation and
mRNA stability, which contribute to the multiple fea-
tures of DM1.3 However, the alternative splicing of
many different transcripts fails to fully explain muscle
wasting in DM1 patients. DM1 is a multi-systemic
disease that affects many organs and tissues besides
muscle.4 DM1 has been described as a disease charac-
terized by premature aging, which involves oxidative
stress in its pathogenesis.5 Reduced or increased cellular
antioxidant activity and increased oxidative stress par-
ameters have been reported in DM1, which may be
associated with muscular and extra-muscular signs of
the disease.5–8 There is considerable evidence suggesting
that reactive oxidative species (ROS) and reactive nitro-
gen species, such as superoxide (O2
.−) and nitric oxide
(NO.), can play roles in age-related loss of muscle
mass and function.9 The inability of aged muscle to
respond to stress is explained by deteriorating redox sig-
naling processes and redox-mediated adaptation.10
Current knowledge supports the likelihood that inter-
actions between the primary genetic defect and disrup-
tions in the normal production of free radicals
contribute to muscle atrophy in muscular dystrophies.10
The inability of muscle regeneration to keep up with
apoptotic and necrotic events following oxidative
stress during normal muscular exercise may underlie
muscle atrophy in DM1.11 In sporadic and familiar
amyotrophic lateral sclerosis, also characterized by
muscle wasting, decreased levels of both copper–zinc
superoxide dismutase (SOD1) and catalase (CAT)
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activities in erythrocytes have been described.12 Thus,
circulating oxidative stress could be related to skeletal
muscle wasting in DM1.
The aim of our study was to analyze the levels of
antioxidant defense enzymes in erythrocytes of
patients with DM1, to compare them with those in
healthy controls (HCs) and to correlate individual
antioxidant enzyme activity with DM1 clinical data,
Muscular Impairment Rating Scale (MIRS) scores
and creatine kinase (CK) levels. Erythrocytes are a
good model for studying systemic oxidative stress
and have been exploited in other studies.12
Methods
Patients selection
This cross-sectional study comprised 30 (14 males and
16 females) adult patients aged 41± 5 years primarily
diagnosed with DM1, who were examined in the out-
patient and inpatient units of the Neurology Clinic in
Belgrade from 1 September until 31 December 2011
and 15 HCs matched for gender (seven males and
eight females) age 36± 5 years. Patients with congeni-
tal and late adult form of DM1 were not included. In
addition to standard clinical and electromyography
data, genetic diagnosis of CTG repeat expansion was
obtained from all the patients (mean was 691± 57).
The study was approved by the Ethical Board of the
Neurology Clinic, University of Medical Sciences,
Belgrade, N° 29/X-5. All patients gave informed
written consent to participate in the study.
The severity of DM1 was assessed by the MIRS
(mean was 3.4± 0.2).13 The MIRS is an ordinal five-
point rating scale established in accordance with the
clinically recognized distal to proximal progression
of muscular involvement in DM1. The man level of
serum CK in patients was 251± 50 IU/l.
Biochemical analysis
Each study participant donated a 5 ml blood sample
obtained by venous puncture between 8 and 9 a.m.
after an overnight fast and a period of tobacco absti-
nence (overnight 12 hours). Erythrocyte lysates were
prepared as follows. After the heparin-treated blood
samples were centrifuged at 2000 × g for 15 minutes
at 4°C, the plasmawas discarded. The separated eryth-
rocytes were washed three times with 0.9%, w/v NaCl.
Washed cells (0.5 ml) were then lysed by adding 3 ml
of ice-cold distilled water followed by thorough
mixing.
Hemoglobin (Hb) concentration
The total Hb content of the hemolysates was measured
as cyanmethemoglobin using the Drabkin method.14
Hemoglobin removement
To remove Hb 1.0 ml of an ethanol/chloroform (1:1,
v/v) mixture was added to an aliquot (0.5 ml) of the
hemolysate cooled on ice.15 This mixture was stirred
constantly for 15 minutes before being diluted with
0.5 ml of distilled water. After centrifugation for 10
minutes at 1600 × g, the pale-yellow supernatant was
separated from the protein precipitate and was used
to assay SOD enzyme activity spectrophotometrically
and for native polyacrylamide gel electrophoresis
(PAGE).
Spectrophotometric measurements
Antioxidant enzyme activities were measured as pre-
viously described.12
SOD1 activity was determined by the epinephrine
method, which is based on the capacity of SOD1 to
inhibit autoxidation of adrenaline to adrenochrome.
Reaction mixtures consisted of 3 × 10−4 M adrenaline,
1 × 10−4 M EDTA, and 0.05 M Na2CO3, pH 10.2.
One unit of SOD is defined as the amount of protein
causing 50% inhibition of the autoxidation of
adrenaline.
CAT activity is defined as the amount of enzyme,
which decomposes 1 mmol hydrogen peroxide
(H2O2) in 1 minute at pH 8.0 in 1 M Tris–5 mM
EDTA buffer measured at 230 nm.
GSH-Px—glutathione peroxidase activity was
measured according to NADPH consumption
(NADPH oxidation by glutathione reductase) moni-
tored at 340 nm. The reaction mixture consisted of
50 mM potassium phosphate buffer (pH 7.0), 1 mM
EDTA, 1 mMGSH, 1 mM sodium azide, 1 U/ml glu-
tathione reductase, 0.2 mM NADPH, and 3 mM
t-butyl hydroperoxide.
GR—glutathione reductase activity measurement is
based on NADPH oxidation concomitant with GSH
reduction. The reaction mixture consisted of 0.5 M
sodium phosphate buffer (pH 7.5), 0.1 mM EDTA,
0.1 mM NADPH, and 0.1 mM GSSG. Enzyme
activity is expressed in U/g of soluble protein. One
unit of enzyme activity is defined as the amount of
enzyme required to transform 1 μmol of substrate per
minute under the above described assay conditions.
Native PAGE
Was performed according to Laemmli, 1970 using
12% acrylamide under non-denaturing conditions.16
Prior to PAGE, aliquots of SOD1 from erythrocytes
were incubated for 2 hours at 37°C with gentle stirring
in the absence (control) and presence of 5 mM H2O2.
Incubated SOD samples were diluted to 2 U/ml using
a solution containing 12% glycerol, 0.5 mM Tris–HCl
(pH 6.8), and 0.2 M EDTA before loading 50 μl per
well. SOD1 bands (achromatic zones on an otherwise
uniformly violet-blue gel) were visualized using the
activity staining procedure described by Beauchamp
and Fridovich17 requiring the reduction of nitroblue
tetrazolium (NBT) with superoxide produced by
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photochemical reduction of riboflavin with
N,N,N′,N′,-tetramethylethylenediamine. To quantify
SOD activity, the gels were scanned using a densi-
tometer (GS-700, Bio-Rad) and the tiff image files
were analyzed using Multi-Analyst 1.0.2 software
(Bio-Rad).
Statistical analysis
Statistical analyses were performed according to the
protocols originally described by Manley18 and
Blagojević et al.,19 which have been subsequently
applied to study other pathophysiological con-
ditions.12,20 Differences in antioxidant enzyme activity
between DM1 patients and controls were analyzed by
one-way analysis of variance (ANOVA) followed by
Tukey’s Student’s t-test. Spearman’s coefficient was
used for correlation of two variables. Since correlation
analysis calculates relationships between individual
components, we performed canonical discriminant
analysis that calculated differences between groups,
taking into consideration the complete correlation
matrix (i.e. composition of antioxidant defense) of sep-
arate patient groups. In all analyses, P< 0.05 was con-
sidered as significant.
Results
The activities of SOD1 and CAT were lower in DM1
patients compared to HCs (Fig. 1).
Other measured antioxidant enzymes (GSH-Px and
GR) showed no differences. In-gel SOD activity
showed the same result (lower activity of SOD1 in
DM1 patients compared to HCs). Figure 2 illustrates
a representative SOD1 activity profile in non-denatur-
ing PAGE conditions. In addition, SOD1 in HCs was
more active (45% of activity remaining; P< 0.05) after
partial inhibition with equimolar concentration of
H2O2, compared to that in DM1 patients (25% activity
remaining; P< 0.001).
When DM1 patients were segregated according to
MIRS grade score, SOD1 activity in erythrocytes of
DM1 patients with MIRS grades III and IV was sig-
nificantly lower than HCs (Table 1). Differences in
CAT activity were just above the threshold for a stat-
istically acceptable ANOVA P value (therefore the
post hoc test showed no statistical significance). The
activities of GSH-Px and GR were not different com-
pared to those found in HCs.
Figure 1. Antioxidant enzyme activities in erythrocytes from
DM1 patients (n= 30) and HCs (n= 15). Results are expressed
asmean± SE and compared by t-test. ***P< 0.001, **P< 0.01.
Figure 2. Native PAGE gel stained for SOD1 enzyme activity
with NBT. Lanes, from left to right: HCs; HCs+H2O2; DM1 and
DM1+H2O2. Histogram presents quantitative analysis of SOD
activity. Graphs represent % from SOD activity HCs taken as
100% (±SE). Statistical analysis showed a more pronounced
reduction in activity after H2O2 treatment of DM1 SOD
compared with to HC SOD (***P< 0.001; n= 7, vs. *P< 0.05;
n= 5). Note the difference between samples with respect to
relative band intensity (in-gel SOD1 activity). For details, see
‘Methods’ section.
Table 1 The activity of antioxidant enzymes in DM1 patients
with different severity of muscle impairment
SOD1 CAT GSH-Px GR
HCs (n= 15) 3.0± 0.2a 26.9± 2.2 24.3± 1.4 8.1± 0.5
DM1 MIRS II
(n= 4)
2.5± 0.2ab 18.9± 3 22.3± 1.4 7.9± 0.7
DM1 MIRS III
(n= 11)
1.6± 0.2b 20.8± 2.3 24.5± 2.1 8.8± 1.0
DM1 MIRS IV
(n= 11)
1.9± 0.2b 20.7± 2.2 22.7± 1.7 9.0± 1.0
DM1 MIRS V
(n= 4)
2.3± 0.3ab 15.7± 0.2 26.3± 1.2 8.6± 1.0
ANOVA P< 0.001 N.S. N.S. N.S.
Results are expressed as mean± SE and tested by one-way
ANOVA followed by Tukey’s HSD test (different letters (a) or (b)
mean statistical significant difference between groups; (ab)
means no significant difference in comparison with the other
groups). N.S. — not significant.
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After segregating the patients according to their
CK levels, normal (60–174 IU/l) or increased
(>180 IU/l), SOD1 was still statistically lower in
both groups of DM1 patients compared to HCs.
However, CAT activity was significantly lower only
in DM1 patients with increased CK (Table 2). GSH-
Px and GR activities were not different compared to
HCs.
Inter-correlations between the activities of different
antioxidant enzymes and clinical parameters as well
as MIRS score, CK levels, and CTG number in
DM1 patients are shown in Table 3.
There were no significant correlations between the
level of measured antioxidant enzymes and clinical
parameters (age of patients, disease duration, age of
disease onset), clinical MIRS scores, CK levels, and
CTK number, except for GR activity [it was signifi-
cantly positively correlated with duration of the
disease (σ= 0.42, P< 0.05). In contrast, significant
positive correlations were found between antioxidant
enzyme activities in DM1 patient erythrocytes: CAT
versus GSH-Px (P< 0.001), CAT versus GR (P<
0.05), and GSH-Px versus GR (P< 0.05).
As antioxidant enzymes form complex inter-con-
necting physiological functions, we performed canoni-
cal discriminant analysis between different groups of
patients and HCs. Canonical discriminant analysis sig-
nificantly separated DM1 patients with MIRS III (P<
0.001) and MIRS IV (P< 0.01) scores from HCs. The
composition of antioxidant enzymes in MIRS II and
MIRS V groups was not significantly different from
that in HCs (Fig. 3A).
Furthermore, there were no differences in the com-
position of antioxidant enzymes in patients with differ-
ent CK levels (CK normal and CK increased), but
both groups of patients (CK normal and CK
increased) had a different composition compared to
HCs (Fig. 3B). For all comparisons SOD1 activity
was most dominant (P< 0.001).
Discussion
Our results clearly showed decreased SOD1 activity in
DM1 patient erythrocytes compared to HCs. The
decrease in SOD1 activity may have been caused by
H2O2-mediated inhibition,
21 as demonstrated by
native PAGE (Fig. 2). After partial inhibition with
H2O2, SOD1 activity was more reduced in DM1
patients than in HCs. It is well known that H2O2 inhi-
bits SOD1 activity. In addition, H2O2 directly
degrades the enzyme itself.20 It appears that SOD1 in
DM1 patients is more susceptible to this process
(Fig. 2). Previous studies have shown increased apop-
tosis in myogenic cell lines possessing increased
number of CTG repeats after administration of
methylmercury, a known ROS producer.22 Advanced
oxidation protein products are significantly higher in
sera of DM1 patients compared to HCs.10 These find-
ings are in line with our own results, which suggest that
Table 2 Comparison of antioxidant defense in HCs and DM1 patients with normal and increased CK values
SOD1 CAT GSH-Px GR
HCs (n= 15) 3.04± 0.24a 27± 2a 24.3± 1.4 8.1± 0.5
DM1 patients – CK normal 1.88± 0.21b 22.2± 2.2ab 22.7± 2 9.2± 1.2
DM1 patients – CK increased 1.91± 0.18b 19.8± 1.8b 25.6± 1.3 8.4± 0.5
ANOVA P< 0.001 P< 0.05 N.S. N.S.
Results are expressed as mean± SE and tested by one-way ANOVA followed by Tukey’s HSD test (different letters (a) or
(b) mean statistical significant difference between groups; (ab) means no significant difference in comparison with the other groups).
N.S. – not significant.














Disease duration −0.32 0.44* 0.09
Age 0.60** 0.32 −0.18 0.57**
Duration/age −0.64*** 0.36 0.14 0.88*** 0.18
CTG number −0.42 0.06 0.17 −0.07 −0.40 0.21
SOD1 0.15 −0.07 0.18 0.15 0.25 −0.01 −0.31
CAT −0.18 −0.04 0.12 0.25 0.07 0.21 0.36 0.19
GSH-Px 0.18 0.05 0.17 0.14 0.27 −0.05 0.27 0.34 0.71***
GR −0.04 0.08 −0.16 0.42* 0.01 0.31 0.17 −0.01 0.39* 0.47*
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there is a certain degree of disturbance in the activity
of antioxidant enzymes in DM1 patients. Decreased
levels of antioxidant enzymes in blood samples from
DM1 patients, including decreased SOD, have also
been reported.23 In contrast, earlier reports showed
increased SOD1 activity.5 These latter activities were
measured in blood serum and could have been a reflec-
tion of erythrocyte lysis, or other interfering sub-
stances. In our current study, decreased SOD1
activity was measured in erythrocytes. This finding
could represent a suppressive reaction to increased oxi-
dative stress during a particular phase of the disease,
since SOD1 activity from DM1 patients are more sus-
ceptible to H2O2-mediated inhibition. Additionally, in
our cohort of patients, decreased SOD1 activity was
particularly pronounced in patients with moderate
muscular impairment severity (MIRS grades III and
IV). This was confirmed by canonical discriminant
analysis, as DM1 patients with MIRS III and IV
scores were significantly separated from other groups
when taking into account the composition of antioxi-
dant enzymes in erythrocytes. These results also
demonstrated that oxidative stress in DM1 patients is
dynamic and changeable during the disease stages.
Furthermore, the activity of antioxidant enzymes in
erythrocytes did not correlate with MIRS score
suggesting that oxidative stress and involvement of
particular ROS is stage specific and does not linearly
follow disease progression. Moreover, the activity of
antioxidant enzymes in erythrocytes was not corre-
lated with either CK level nor CTG number, although
SOD1 and CAT activities were lower in DM1 patients
regardless if CK levels were elevated (our results
showed that CAT activity was significantly decreased
only in patients with increased CK, but the signifi-
cance was slightly below the confidence limit, P<
0.05). It has been shown that CK concentration is
often, but not always, elevated in muscle disease.24
Our results suggest that there is an association
between muscle deterioration, increased CK levels
and CAT inhibition in erythrocytes.
The effect of oxidative stress on muscle damage has
been shown to be present in muscular diseases such as
dystrophinopathy,11 mitochondrial disorders25 and in
sarcopenia, which is age-related muscle loss.5
Normal muscle tissue responds to the stress of contrac-
tions by up-regulating protective enzymes (including
SOD1 and CAT) and stress proteins.5,26 The primary
reactive species generated by muscle, both at rest and
during contraction, are NO. and O2
.−.27 Small
increases in reactive species are favorable and lead to
increased force production. Greater production of
reactive species contributes to the development of
muscle fatigue.28 The predominant effects of ROS
and NO· on muscle force production are due to
changes in calcium metabolism influenced by the rya-
nodine receptor and sarcoplasmic reticulum Ca2+
ATPase-SERCA.29 Interestingly, both mRNAs of
these proteins are mis-spliced in DM.30
Since the above-mentioned mechanisms lead to
aging in normal muscle tissue, they are also probably
related to progeroid processes in DM1.4 In line with
this, there is evidence that increased cellular O2
.− can
cause muscle ageing since mice lacking SOD1 exhib-
ited accelerated age-related loss of skeletal muscle
mass and function.31 At present treatment for DM1
is limited to symptomatic intervention and there is
no therapeutic approach to prevent or reverse disease
progression.32 As oxidative stress plays a role in the
progression of neurodegeneration and muscle
wasting,33 there is a possibility that supplemented anti-
oxidant therapy could be beneficial, particularly at
intermediate stages of DM1, when decreased SOD 1
is present.
In physiological settings erythrocytes exhibit a self-
sustaining activity of antioxidant defense enzymes
Figure 3. Canonical discriminant analysis of the activity of
antioxidant enzymes in different forms of DM1 according to
(A) different severity of MIRS and (B) CK levels, presented as
two-dimensional canonical space. Canonical analysis
significantly separated DM1 patients with MIRS III and IV
stages from HCs and the other two stages (P< 0.001). DM1
patients were significantly separated from HCs regardless if
CK levels were increased (P< 0.001).
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and their coordinated actions protect the erythrocytes’
bio-macromolecules from free radical-mediated
damage. This is the case in this current study, as posi-
tive correlation was found between CAT, GSH-Px,
and GR activities in erythrocytes suggesting that
erythrocytes adjust their antioxidant potential accord-
ing to the presence of oxidative pressure especially by
H2O2. However, we found that there was no significant
correlation between the activity of the antioxidant
enzymes and the clinical outcome. Therefore, the
measurement of the activity of these enzymes cannot
be exploited for diagnostics, but instead suggests that
oxidative processes occur in DM1 patients providing
new insight into the disease.
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DR, Spasić MB. Alterations in anti-oxidative defense enzymes
in erythrocytes from sporadic amyotrophic lateral sclerosis
(SALS) and familial ALS patients. Clin Chem Lab Med
2006;44:589–93.
13 Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P.
Assessment of a disease-specific muscular impairment rating
scale in myotonic dystrophy. Neurology 2001;56(3):336–40.
14 Tentori L, Salvati AM. Hemoglobinometry in human blood.
Methods Enzymol 1981;76:707–15.
15 Tsuchihashi M. Zur Kenntnis der Blutkatalase. Biochemistry
1923;Z140:65–74.
16 Laemmli UK. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature 1970;227:
680–85.
17 Beauchamp C, Fridovich I. Superoxide dismutase: improved
assays and an assay applicable to acrylamide gels. Anal
Biochem 1971;44:276–87.
18 Manley BFJ. Multivariate statistical methods. A primer.
London: Chapman and Hall; 1986.
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